Phases, active trials: Phase 1: 17, Phase 2: 18, Phase 3: 23, Other: 3
Incyte has built a focused clinical portfolio around kinase inhibition — JAK, FGFR, and IDH — with growing programs in checkpoint inhibition and CSF1R-targeted therapy. Jakafi (ruxolitinib), the first JAK1/2 inhibitor approved, remains central across myelofibrosis, polycythemia vera, and acute/chronic graft-versus-host disease. Opzelura (ruxolitinib cream) extends the JAK franchise into dermatology — approved for atopic dermatitis and vitiligo, with ongoing trials in additional inflammatory skin conditions. Pemazyre (pemigatinib) pioneered FGFR inhibition in cholangiocarcinoma and myeloid/lymphoid neoplasms with FGFR1 rearrangements. Zynyz (retifanlimab), their PD-1 inhibitor, is approved in Merkel cell carcinoma and anal canal carcinoma, with expansion trials ongoing. Niktimvo (axatilimab), targeting CSF1R in chronic GvHD, represents a new mechanism in allogeneic transplant complications.
- Hematology (myelofibrosis, PV, GvHD)
- Oncology (FGFR, PD-1, IDH)
- Dermatology (atopic dermatitis, vitiligo)
- Bone marrow failure / transplant complications
- Solid tumors (cholangiocarcinoma, anal carcinoma)
- Jakafi (ruxolitinib) — JAK1/2, myelofibrosis/PV/GvHD
- Opzelura (ruxolitinib cream) — JAK1/2, atopic dermatitis/vitiligo
- Pemazyre (pemigatinib) — FGFR1/2/3, cholangiocarcinoma/FGFR1 neoplasms
- Zynyz (retifanlimab) — PD-1, Merkel cell/anal carcinoma
- Niktimvo (axatilimab) — CSF1R, chronic GvHD
- INCB57643 — BET bromodomain, AML/solid tumors
Monitor the Incyte pipeline daily
Get a daily digest when Incyte registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Solid Tumors | 7 |
| Chronic Graft-versus-host-disease | 6 |
| Myeloproliferative Neoplasms | 5 |
| NonSegmental Vitiligo | 4 |
| Atopic Dermatitis | 3 |
| Healthy Participants | 3 |
| Hidradenitis Suppurativa | 3 |
| Hidradenitis Suppurativa (HS) | 3 |
Incyte's JAK inhibitor expansion — particularly Jakafi combinations in myelofibrosis (with BCL-2, BET inhibitors) and Opzelura label expansions in dermatology — generates consistent new trial registrations. Their FGFR inhibitor portfolio (pemigatinib, futibatinib partnership) is closely tracked in cholangiocarcinoma and urothelial cancer by oncology BD teams.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Incyte's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Incyte may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Incyte pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric… NCT06548360 | Recruiting | Completion pushed: 2027-03-13 → 2028-12-20 | 2026-09-15 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric… NCT07124078 | Recruiting | Primary endpoint(s) modified | 2026-08-26 |
| A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously… NCT07522073 | Recruiting | Trial sites expanded: 219 → 229 locations | 2026-09-16 |
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in… NCT07214779 | Recruiting | Trial sites expanded: 181 → 192 locations | 2026-09-16 |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy… NCT07284849 | Recruiting | Trial sites expanded: 254 → 280 locations | 2026-09-16 |
Each trial page shows every change DataLookout has recorded for that trial.